Drugs.com
APRIL 10, 2025
THURSDAY, April 10, 2025 -- Five years after COVID-19 first hit the United States, scientists are already brainstorming how to stop the next big virus.One possible solution? A special kind of ultraviolet light called far-UVC, CBS News.
Science Daily: Pharmacology News
APRIL 7, 2025
What if we spend decades building advanced telescopes to search for life on other planets and come up emptyhanded? A recent study exploring what we can learn about life in the universe -- even if we don't detect signs of life or habitability. Using advanced statistical modeling, the research team sought to explore how many exoplanets scientists should observe and understand before declaring that life beyond Earth is either common or rare.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
APRIL 7, 2025
As our understanding of the underlying biology of disease grows more sophisticated, emerging therapies operate on increasingly complex biopathological systems and mechanisms. Advanced strategies and tools are being implemented to establish the safety and efficacy of new therapeutic modalities, with the development of new biomarkers becoming one of the most relevant approaches for enhancing the precision and utility of early-stage studies.
Perficient: Drug Development
APRIL 7, 2025
Metadata contention in Unity Catalog can occur in high-throughput Databricks environments, slowing down user queries and impacting performance across the platform. Our Finops strategy shifts left on performance. However, we have found scenarios where clients are still experiencing query slowdowns intermittently and even on optimized queries. As our client’s lakehouse footprint grows, we are seeing an emerging pattern where stress on Unity Catalog can have a downstream drag on performance a
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Covalent Modifiers
APRIL 9, 2025
Dennis H. Kim and Watson J. Lees Biochemistry 2025 DOI: 10.1021/acs.biochem.4c00522 The antibiotic fosfomycin is an epoxy-phosphonate natural product with a broad spectrum of antibacterial activity and distinct mechanism of action that has been in clinical use for 50 years. Fosfomycin is an irreversible covalent inhibitor of UDP-GlcNAc enolpyruvyl transferase (MurA), which catalyzes the first committed step in bacterial peptidoglycan biosynthesis.
Sygnature Discovery
APRIL 7, 2025
Introducing a novel payload -focused approach to next generation ADC development NewPath ADC offers integrated solutions for antibody drug conjugates, designed by highly skilled multidisciplinary teams covering medicinal chemistry and protein sciences, as well as in vitro and in vivo assessment (including DMPK). While other providers focus on a conventional, well-trodden development pathway, Sygnature Discovery’s ADC solutions prioritize payload optimization to enhance a drugs efficacy a
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
FDA Law Blog: Biosimilars
APRIL 7, 2025
By Sara W. Koblitz & Dara Katcher Levy Promotional claims do not receive the most attention with respect to FDA enforcement these days, and veterinary promotion is no exception. Indeed, most Center for Veterinary Medicine (CVM) Warning Letters arise because products advertised are actually new animal drugs. But this year, CVM has issued two notable warning letters and one Untitled Letter concerning the promotion of animal drugs that caught our attention because of the level of detail and sp
Broad Institute
APRIL 5, 2025
David Liu receives Breakthrough Prize in Life Sciences By Corie Lok April 5, 2025 Breadcrumb Home David Liu receives Breakthrough Prize in Life Sciences Liu is honored for the development of base editing and prime editing, two gene editing technologies transforming medicine. By Broad Communications April 5, 2025 Credit: Casey Atkins David Liu is a core member at the Broad Institute where he is the Richard Merkin Professor and director of the Merkin Institute for Transformative Technologies in He
New Drug Approvals
APRIL 11, 2025
Fitusiran 1711.0g/mol, C 78 H 139 N 11 O 30 FDA APPROVED 3/28/2025, Qfitlia , To prevent or reduce the frequency of bleeding episodes in hemophilia A or B Press Release CAS 1499251-18-1 EX-A12034 DA-53206 N-[1,3-Bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4
Drug Patent Watch
APRIL 10, 2025
"Just spent the morning digging into the world of pharmaceuticals and I'm blown away by the complexities of drafting effective drug patent applications. The team at Drug Patent Watch has done an incredible job of breaking down the key considerations for turning scientific discoveries into market power. From understanding the nuances of patent law to leveraging data-driven strategies, it's clear that the stakes are high in this space.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce BioTech
APRIL 7, 2025
Why speed and clinical accuracy of information and data is critical for physicians Learn how speed and accuracy of clinical information is transforming healthcare delivery and how your brand can become part of these high-value clinical conversations at the point of decision-making. Download now. sdees Mon, 04/07/2025 - 10:57 Learn how speed and accuracy of clinical information is transforming healthcare delivery and how your brand can become part of these high-value clinical conversations at the
Perficient: Drug Development
APRIL 7, 2025
Migrating from Eloqua to Salesforce Marketing Cloud: A Step-by-Step Guide Transitioning from Oracle Eloqua to Salesforce Marketing Cloud (SFMC) is a significant move that can unlock new capabilities, improve personalization, and better align your marketing stack with your broader Salesforce ecosystem. However, its not just a matter of copying and pasting your assets over a successful migration requires thoughtful planning, collaboration, and execution.
FDA Law Blog: Biosimilars
APRIL 7, 2025
Come together with leaders from the pharmaceutical, biotechnology, and diagnostic industries to unpack huge changes at the American Conference Institutes 23rd Advanced Summit on Life Sciences Patents , which is scheduled to take place from May 19-20, 2025 at the New York Bar Association in New York, NY. In a year of major change and outstanding questions, growing scrutiny on patent protection and drug pricing, and uncertainty around global price control measures and the Inflation Reduction Act,
Drug Patent Watch
APRIL 8, 2025
"5 Key Considerations for Valuing Pharma Companies As the pharmaceutical industry continues to evolve, accurately valuing pharma companies has become increasingly complex. At DrugPatentWatch, we've identified 5 key considerations that can help you make informed investment decisions. Patent Portfolio Strength : A strong patent portfolio can significantly impact a company's valuation.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Conversations in Drug Development Trends
APRIL 7, 2025
Solid tumors present a significant challenge to clinical research due to their complex and heterogeneous nature. However, the emergence of precision medicine is revolutionizing the way we approach these tumors, offering new hope and innovative solutions. Have you optimized your trial designs to employ precision medicine approaches for your novel solid tumor intervention?
Perficient: Drug Development
APRIL 10, 2025
Welcome to our new series on Universal Design for Pharmacies! In this segment, well explore the importance of Universal Design in Pharmacies for All Disabilities. As pharmacies continue to expand their digital presence, providing services through websites and mobile platforms, ensuring accessibility is crucial. The Web Content Accessibility Guidelines (WCAG) principle of Operable is key to creating interactive and navigable platforms for all users, including individuals with disabilities.
FDA Law Blog: Biosimilars
APRIL 10, 2025
By Sarah Wicks & Anne K. Walsh The recent and drastic Reduction In Force (RIF) at the U. S. Food and Drug Administration (FDA) is already having ripple effects not just internally, but across the broader regulatory and life sciences communities and the public at large. While much of the focus has been on how these cuts may impact application review timelines and industry engagement, see earlier post about the effect on generic drugs, another quieter consequence is emerging a significant sl
Drug Patent Watch
APRIL 8, 2025
Patient Safety in the Era of Generic Drugs: A Call to Action As the pharmaceutical industry continues to evolve, one thing remains constant: the need for patient safety. With the rise of generic drugs, it's more important than ever to ensure that these alternatives meet the same high standards as their brand-name counterparts. At DrugPatentWatch, we've seen firsthand the impact that generic drugs can have on patients.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Conversations in Drug Development Trends
APRIL 8, 2025
In a recent webinar, Challenges of Drug Development in Early Parkinsons Disease , Tom Babic, MD, PhD , our Vice President of Scientific Solutions in Neuroscience, uses his 40+ years of experience to share invaluable insights into the current state and future directions of early Parkinsons disease (PD) research. Although clinical research in PD began more than 25 years ago, there have been no significant updates in the last decade.
Perficient: Drug Development
APRIL 10, 2025
This guide will walk you through building a small application step-by-step, focusing on integrating several powerful tools and concepts essential for modern Android development. What We’ll Cover: Jetpack Compose: Building the UI declaratively. NoSQL Database (Firestore): Storing and retrieving data in the cloud. WorkManager: Running reliable background tasks.
Science Daily: Pharmacology News
APRIL 10, 2025
Study reveals commonly detected environmental levels of clobazam -- a medication often prescribed for sleep disorders -- increased the river-to-sea migration success of juvenile salmon in the wild. The research team employed slow-release pharmaceutical implants and animal-tracking transmitters to monitor how exposure to clobazam and the opioid painkiller tramadol -- another common pharmaceutical pollutant -- affected the behaviour and migration of juvenile Atlantic salmon (Salmo salar) in Sweden
FDA Law Blog: Biosimilars
APRIL 8, 2025
By Kurt R. Karst The FDA Reduction-in-Force (Termination)or RIF(T)announced last week has resulted in countless stories in the press and on personal LinkedIn accounts from those RIFd. As the dust begins to settle and we all assess what this means for the future of FDA and the public health, generally, this blogger wanted to call out one particular division in the Office of Generic Drugs (OGD), funded by user fees under the Generic Drug User Fee Amendments (GDUFA), that was eradicated and what t
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
APRIL 9, 2025
Patient-Centric Approaches to Maintaining Brand Value As the pharmaceutical industry continues to evolve, one thing remains clear: patients are at the forefront of every decision. At DrugPatentWatch, we've seen firsthand how patient-centric approaches can make all the difference in maintaining brand value. In our latest blog post, we explore the importance of putting patients first in brand strategy.
Perficient: Drug Development
APRIL 10, 2025
Welcome to our new series on Universal Design for Pharmacies! In this segment, well explore the importance of Universal Design in Pharmacies for All Disabilities. In the digital space, pharmacies are increasingly using websites and online platforms to enhance customer service, facilitate prescription refills, and provide health-related information. To ensure inclusivity, applying the Web Content Accessibility Guidelines (WCAG) principle of Perceivable is vital.
ProRelix Research
APRIL 8, 2025
Struggling with multi-country clinical trials? Overcome regulatory hurdles, patient recruitment challenges, and data complexities with a true CRO partner. Introduction Carrying out a multi-country clinical trial is indeed an arduous […] The post A True CRO Partner for Your Multi-Country Clinical Trial appeared first on ProRelix Research.
Science Daily: Pharmacology News
APRIL 9, 2025
Wear and tear on plastic products releases small to nearly invisible plastic particles, which could impact people's health when consumed or inhaled. To make these particles biodegradable, researchers created plastics from plant starch instead of petroleum. An initial study shows how animals consuming particles from this alternative material developed health problems such as liver damage and gut microbiome imbalances.
Drug Patent Watch
APRIL 7, 2025
"Unlocking the Secrets of CDMO Pricing: A Game-Changer for Life Sciences As a seasoned professional in the life sciences industry, I've seen firsthand the impact of Contract Development and Manufacturing Organization (CDMO) pricing on the bottom line. But with so many variables at play, it can be daunting to navigate the complex world of CDMO pricing.
FDA Law Blog: Biosimilars
APRIL 6, 2025
Hyman, Phelps & McNamara (HPM) marks its 45thAnniversary year by welcoming three accomplished professionals who reinforce the depth and breadth of the firms FDA and DEA practices. Naomi Lowy joins HPM as a Principal Drug Regulatory Expert after 18 years at the FDAs Center for Drug Evaluation and Research (CDER), most recently as the Deputy Director, Division of General Endocrinology.
Crucial Data Solutions
APRIL 10, 2025
Why Wearable Tech Is Changing Clinical Trials Wearable devices are doing more than counting stepstheyre redefining how clinical trials are. The post How Wearable Devices Improve Patient Engagement in Clinical Trials appeared first on Crucial Data Solutions.
Drug Channels
APRIL 9, 2025
It's time for Drug Channels annual update of vertical integration among insurers, PBMs, specialty pharmacies, and healthcare services within U.S. drug channels. As you can see below, we have revised, renovated, and refurbished our infamous illustration of the major vertical business relationships among the largest companies. Proponents of these vertical integration arrangements argue that they create opportunities to mine healthcare costs.
Drug Patent Watch
APRIL 9, 2025
"Market Domination Through Cost Optimization: A Game-Changer for Generic Drug Manufacturers As the pharmaceutical industry continues to evolve, generic drug manufacturers are facing increasing pressure to reduce production costs while maintaining quality and regulatory compliance. At DrugPatentWatch, we've identified key strategies to help generic drug manufacturers optimize their production costs and gain a competitive edge in the market.
FDA Law Blog: Biosimilars
APRIL 11, 2025
By Andrew J. Hull Last month, we blogged on the Department of Justices (DOJ) abrupt announcement that it had determined that removal restrictions protecting administrative law judges (ALJs) were unconstitutional and that DOJ would no longer defend those removal restrictions in court. We opined that while the impact of this statement was unclear, it was likely that this position would make it more difficult for litigants challenging the constitutionality of a proceeding presided by an ALJ.
Expert insights. Personalized for you.
263 
Let's personalize your content